Literature DB >> 2840013

Fluconazole and testosterone: in vivo and in vitro studies.

D P Hanger1, S Jevons, J T Shaw.   

Abstract

Fluconazole (UK-49,858), a novel bis-triazole antifungal agent, was given orally to groups of 10 male volunteers at doses of 25 and 50 mg/day for 28 days. Blood samples for testosterone estimation were taken from these and from a placebo group at several time points on days 1, 14, and 28 of the study, and the assay results demonstrated that the compound had no significant effect on circulating testosterone levels. Similarly, in studies with rat Leydig cells in vitro, fluconazole at concentrations up to 10 micrograms/ml was found to be only a weak inhibitor of testosterone production, whereas ketoconazole caused more than 50% inhibition at 0.1 microgram/ml. It is concluded that fluconazole, in contrast to ketoconazole, has little effect on the biosynthesis of testosterone by mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840013      PMCID: PMC172246          DOI: 10.1128/AAC.32.5.646

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Authors:  P R Wood; M H Tarbit
Journal:  J Chromatogr       Date:  1986-11-28

3.  Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Acta Endocrinol (Copenh)       Date:  1984-02

4.  High-dose ketoconazole therapy and adrenal and testicular function in humans.

Authors:  A Pont; J R Graybill; P C Craven; J N Galgiani; W E Dismukes; R E Reitz; D A Stevens
Journal:  Arch Intern Med       Date:  1984-11

5.  In vitro inhibition of testosterone biosynthesis by ketoconazole.

Authors:  S C Sikka; R S Swerdloff; J Rajfer
Journal:  Endocrinology       Date:  1985-05       Impact factor: 4.736

6.  Imidazole antimycotics: inhibitors of steroid aromatase.

Authors:  J I Mason; B A Murry; M Olcott; J J Sheets
Journal:  Biochem Pharmacol       Date:  1985-04-01       Impact factor: 5.858

7.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

Authors:  D S Loose; P B Kan; M A Hirst; R A Marcus; D Feldman
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Site of action of low dose ketoconazole on androgen biosynthesis in men.

Authors:  R J Santen; H Van den Bossche; J Symoens; J Brugmans; R DeCoster
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

10.  Gynecomastia with ketoconazole.

Authors:  R DeFelice; D G Johnson; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

View more
  11 in total

1.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?

Authors:  W Reardon; A Smith; J W Honour; P Hindmarsh; D Das; G Rumsby; I Nelson; S Malcolm; L Adès; D Sillence; D Kumar; C DeLozier-Blanchet; S McKee; T Kelly; W L McKeehan; M Baraitser; R M Winter
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

Review 3.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 4.  New antiviral and antifungal drugs.

Authors:  P G Davey
Journal:  BMJ       Date:  1990-03-24

Review 5.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

6.  Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.

Authors:  M A Touchette; P H Chandrasekar; M A Milad; D J Edwards
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 7.  New antifungal agents for the systemic mycoses.

Authors:  S M Ringel
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

8.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.

Authors:  M A Fisher; P G Lee; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 10.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.